Humanized Anti-Factor D Antibodies And Uses Thereof

Patent metadata

Field	Value
Publication number	US-2016145349-A1
Application number	US-201514948911-A
Country	US
Kind code	A1
Filing date	Nov 23, 2015
Priority date	Apr 28, 2008
Publication date	May 26, 2016
Grant date	—

Abstract

The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.

First claim

1 .- 76 . (canceled)

77 . An isolated polynucleotide encoding an anti-Factor D antibody or an antigen-binding fragment thereof, wherein the anti-Factor D antibody or antigen-binding fragment thereof comprises:
(a) a heavy chain variable domain comprising: i. an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39; ii. an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40; and iii. an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41; and (b) a light chain variable domain comprising: i. an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 30; ii. an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 35; and iii. an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 38; wherein the amino acid residue at position 1 of the heavy chain variable domain is an E.

78 . A vector comprising the polynucleotide of claim 77 .

79 . An isolated host cell comprising the vector of claim 78 .

80 . The host cell of claim 79 , wherein the host cell is eukaryotic.

81 . The host cell of claim 80 , wherein the host cell is a CHO cell.

82 . The host cell of claim 79 , wherein the host cell is prokaryotic.

83 . A method of making an anti-Factor D antibody, wherein the method comprises (a) culturing the host cell of claim 79 under conditions suitable for expression of the polynucleotide encoding the antibody, and (b) isolating the antibody.

Assignees

• Genentech Inc

Inventors

• Huang Arthur
• Kelley Robert
• Lowman Henry
• Van Lookeren Campagne Menno
• Winter Charles

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P27/02

  Ophthalmic agents · CPC title